The AURA2 trial investigated the efficacy of osimeritinib, an irreversible tyrosine kinase inhibitor, in treating patients with advanced NSCLC and either EGFR-TKI sensitizing or EGFR T790M mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.